Key Takeaways
- Current FDA Status: Follistatin 315 is not FDA-approved and is classified for research purposes only.
- Compounding Legality: It cannot be compounded by 503A or 503B pharmacies due to its research-only designation.
- Prescription and Research Use: Available solely for research use; cannot be legally prescribed for therapeutic purposes.
- State-Level Variations: No significant state-level differences in regulation have been documented.
- Patient Implications: Patients should verify clinic legality and be wary of clinics offering unapproved therapies.
Current FDA Status
Follistatin 315 is not approved by the U.S. Food and Drug Administration (FDA) for any medical use. It is categorized as a research-only peptide, meaning it can be used for molecular and cellular research, but not for therapeutic applications in humans. This classification is based on the FDA's current listing of bulk drug substances not eligible for compounding under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) FDA.gov. As of the latest verification in February 2026, Follistatin 315 remains on the list of substances permitted solely for research purposes.
Compounding Status
Under current regulations, Follistatin 315 cannot be compounded by either 503A or 503B pharmacies. The FDA's prohibition is due to its classification as a research-only compound, which means it lacks the necessary safety and efficacy data to support its use in compounded medications. This aligns with the FDA's stance on substances without approved medical applications, as detailed in recent Federal Register notices.
Enforcement Actions
To date, there have been no specific Department of Justice (DOJ) prosecutions or FDA warning letters targeting Follistatin 315. However, the FDA has issued general warnings about the sale and use of research peptides for unapproved uses. Clinics or vendors offering Follistatin 315 for therapeutic purposes could face regulatory scrutiny and potential legal action.
Prescription vs. Over-the-Counter vs. Research Use
Follistatin 315 is legally available only for research use, which means it can be purchased by laboratories for scientific studies but cannot be prescribed by healthcare providers for patient treatment. The term "research use only" signifies that the peptide is intended for laboratory research and not for human or veterinary use in treating conditions. This distinction is critical for understanding the legal limitations surrounding its use.
State-Level Variations
Currently, there are no significant differences in the regulation of Follistatin 315 at the state level compared to federal guidelines. Most states defer to FDA regulations regarding the use of research-only substances, maintaining consistency across jurisdictions.
